Good
Mostly Aligned
Patient Risk:
Low
Summary
Overall alignment is Good. The AI response correctly reflects ACE inhibition as the mechanism, the primary indication for lisinopril (hypertension, in the context of the provided label for lisinopril/HCTZ), and common adverse events. It omits or misstates several non-label claims (e.g., heart failure and post-MI mortality benefits, broader antihypertensive class statements, and patent/generic status). There are also minor gaps in explicitly linking certain statements to the exact label sections. Missed-dose guidance appears to be supported, but some omissions are still present.
Category Scores
Accurate Statements
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor.
Mechanism of Action
ACE inhibitors prevent the conversion of angiotensin I to angiotensin II.
Mechanism of Action
Angiotensin II is a substance that causes blood vessels to narrow and blood pressure to rise.
Mechanism of Action
By blocking this conversion, lisinopril helps blood vessels widen, thus reducing blood pressure.
Mechanism of Action; Indications and Usage; Dosage and Administration
Lisinopril is primarily prescribed to treat high blood pressure (hypertension).
INDICATIONS AND USAGE; DOSAGE AND ADMINISTRATION
Common side effects associated with lisinopril use include dizziness, headache, fatigue, and cough.
ADVERSE REACTIONS
Lisinopril is one of many ACE inhibitors available.
Mechanism of Action
While they all work through the same mechanism of inhibiting ACE, individual drugs within the class may differ in their pharmacokinetics, such as how quickly they are absorbed and eliminated from the body.
Mechanism of Action
This can sometimes influence dosing schedules or suitability for certain patients.
Mechanism of Action; Dosage and Administration
Unsupported Statements
Lisinopril is also used to manage heart failure and to improve survival after a heart attack.
Not supported by INDICATIONS AND USAGE section provided for lisinopril alone or lisinopril/HCTZ combination in this prompt.
Several classes of medications can be used to treat high blood pressure, including other ACE inhibitors, ARBs, calcium channel blockers, diuretics, and beta-blockers.
Not a label assertion specific to lisinopril labeling in the provided sections.
The choice of medication depends on individual patient factors and medical history.
Not a label-specific assertion in the provided lisinopril labeling.
Lisinopril has been available as a generic medication for many years, indicating that its primary patents have expired.
Patent status and expiry are not described in FDA labeling provided.
Information on specific patent expiry dates for older drugs like lisinopril can be found on DrugPatentWatch.com.
External patent resources are not part of FDA labeling.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Heart failure and post-myocardial infarction (mortality) indication for lisinopril; not present in the provided label sections.
Importance:
Moderate
Boxed warnings language (angioedema, hypotension) and explicit wording from WARNINGS/Boxed Warning sections not fully cited in relation to safety risks.
Importance:
High
Drug interaction details are not evaluated or cited from the label sections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Claims largely align with known ACE inhibitor safety profile; no explicit high-risk misstatements identified. Notable omissions pertain to boxed warnings and non-hypertension indications.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omissions of non-hypertension indications (heart failure, post-MI) and boxed warning language; inclusion of generic patent discussion and external resources are outside labeling. Some statements are unsupported by the provided label content.
Suggested Improvement
Anchor statements to exact label sections (INDICATIONS AND USAGE, WARNINGS, ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION); avoid non-label claims (patent status, external websites); clearly state boxed warnings and population-specific considerations (e.g., angioedema risk in Black patients) as per the label.